IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
IMMUNITYBIO, INC. (IBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 358.04 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-04
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 23.82K shares, a 93.00% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 334.22K shares, a 246.73% increase year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 616.38K shares, a 1309.99% increase year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 1.53M shares, a 1422.02% increase year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 2.58M shares, a 485.96% increase from fiscal 2024.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 440.56K shares, a 112.11% increase from fiscal 2023.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 207.71K shares, a 64.40% decline from fiscal 2022.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 583.49K shares, a 370.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 358.04K shares 10-Q · filed 2026-08-04 | 974.42K shares derived: sum of 3 quarters · filed 2026-08-04 | 2.50M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 334.22K shares 10-Q · filed 2026-05-07 | 950.60K shares derived: sum of 2 quarters · filed 2026-05-07 | 2.48M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.82M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 616.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 2.14M shares derived: sum of 2 quarters · filed 2026-02-23 | 2.49M shares derived: sum of 3 quarters · filed 2026-02-23 | 2.58M shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 1.53M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.87M shares derived: sum of 2 quarters · filed 2025-11-05 | 1.97M shares 10-Q · filed 2025-11-05 | 2.01M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 340.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 436.68K shares 10-Q · filed 2025-08-05 | 480.40K shares derived: sum of 3 quarters · filed 2025-08-05 | 580.82K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 96.39K shares 10-Q · filed 2025-05-12 | 140.11K shares derived: sum of 2 quarters · filed 2025-05-12 | 240.53K shares derived: sum of 3 quarters · filed 2025-05-12 | 284.78K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 43.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 144.14K shares derived: sum of 2 quarters · filed 2025-03-03 | 188.38K shares derived: sum of 3 quarters · filed 2025-03-03 | 440.56K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 100.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 144.67K shares derived: sum of 2 quarters · filed 2024-11-12 | 396.85K shares 10-Q · filed 2024-11-12 | 436.96K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 44.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 296.43K shares 10-Q · filed 2024-08-12 | 336.54K shares derived: sum of 3 quarters · filed 2024-08-12 | 401.97K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 252.18K shares 10-Q · filed 2024-05-09 | 292.29K shares derived: sum of 2 quarters · filed 2024-05-09 | 357.72K shares derived: sum of 3 quarters · filed 2024-05-09 | 437.66K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 40.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 105.55K shares derived: sum of 2 quarters · filed 2024-03-19 | 185.48K shares derived: sum of 3 quarters · filed 2024-03-19 | 207.71K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 65.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 145.37K shares derived: sum of 2 quarters · filed 2023-11-09 | 167.59K shares 10-Q · filed 2023-11-09 | 244.84K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 79.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 102.16K shares 10-Q · filed 2023-08-08 | 179.41K shares derived: sum of 3 quarters · filed 2023-08-08 | 286.43K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 22.22K shares 10-Q · filed 2023-05-11 | 99.47K shares derived: sum of 2 quarters · filed 2023-05-11 | 206.49K shares derived: sum of 3 quarters · filed 2023-05-11 | 586.39K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 77.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 184.26K shares derived: sum of 2 quarters · filed 2023-03-01 | 564.16K shares derived: sum of 3 quarters · filed 2023-03-01 | 583.49K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 107.01K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 486.91K shares derived: sum of 2 quarters · filed 2022-11-09 | 506.24K shares 10-Q · filed 2022-11-09 | 506.24K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 379.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 399.23K shares 10-Q · filed 2022-08-08 | 399.23K shares derived: sum of 3 quarters · filed 2022-08-08 | |
| 2022-03-31 | 19.33K shares 10-Q · filed 2022-05-10 | 19.33K shares derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 123.99K shares 10-K · filed 2022-03-01 | ||
| 2021-09-30 | 123.99K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |